Skip to main content
. Author manuscript; available in PMC: 2022 Oct 1.
Published in final edited form as: Trends Immunol. 2021 Sep 2;42(10):856–864. doi: 10.1016/j.it.2021.08.001

Figure 2: Milestones to the development of complement C3-targeted intervention in periodontitis.

Figure 2:

A timeline is shown of key preclinical and clinical studies leading to the development of complement C3-targeted host-modulation using the peptide-based C3 therapeutic AMY-101 as an adjunctive therapy in mammalian periodontal disease (see text for details) [24, 32, 33, 37, 41, 51]. NHP, non-human primates.